FDA OKs Pembrolizumab for Classical Hodgkin Lymphoma FDA OKs Pembrolizumab for Classical Hodgkin Lymphoma

FDA approval was based on tumor response rate and durability of response. Continued approval may hinge on clinical benefits verified and described in confirmatory trials.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news